| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 218.95% | HC Wainwright & Co. | $49 → $34 | Reiterates | Buy → Buy |
| 08/09/2023 | 359.66% | HC Wainwright & Co. | → $49 | Reiterates | → Buy |
| 07/07/2023 | 359.66% | HC Wainwright & Co. | → $49 | Reiterates | Buy → Buy |
| 06/15/2023 | — | TD Cowen | Initiates Coverage On | → Outperform | |
| 06/05/2023 | 359.66% | HC Wainwright & Co. | → $49 | Reiterates | Buy → Buy |
| 05/26/2023 | 359.66% | HC Wainwright & Co. | → $49 | Reiterates | Buy → Buy |
| 05/12/2023 | 359.66% | HC Wainwright & Co. | $50 → $49 | Maintains | Buy |
| 03/27/2023 | 369.04% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 03/10/2023 | 369.04% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 02/15/2023 | 369.04% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 02/03/2023 | 78.24% | Morgan Stanley | $27 → $19 | Maintains | Overweight |
| 11/21/2022 | 87.62% | BTIG | → $20 | Initiates Coverage On | → Buy |
| 05/13/2022 | 134.52% | SVB Leerink | $36 → $25 | Maintains | Outperform |
| 03/18/2022 | 397.19% | HC Wainwright & Co. | $55 → $53 | Maintains | Buy |
| 06/07/2021 | 303.38% | Morgan Stanley | $40 → $43 | Maintains | Overweight |
| 06/04/2021 | 415.95% | HC Wainwright & Co. | $48 → $55 | Maintains | Buy |
| 06/04/2021 | 406.57% | SVB Leerink | $48 → $54 | Maintains | Outperform |
| 04/27/2021 | — | Morgan Stanley | Upgrades | Equal-Weight → Overweight | |
| 04/19/2021 | 275.23% | Morgan Stanley | $38 → $40 | Maintains | Equal-Weight |
| 03/30/2021 | 350.28% | HC Wainwright & Co. | $47 → $48 | Maintains | Buy |
| 02/02/2021 | 415.95% | Evercore ISI Group | → $55 | Initiates Coverage On | → Outperform |
| 02/02/2021 | 387.8% | SVB Leerink | → $52 | Initiates Coverage On | → Outperform |
| 02/02/2021 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight | |
| 02/01/2021 | 340.9% | HC Wainwright & Co. | → $47 | Initiates Coverage On | → Buy |
What is the target price for Cullinan Oncology (CGEM)?
The latest price target for Cullinan Oncology (NASDAQ: CGEM) was reported by HC Wainwright & Co. on August 11, 2023. The analyst firm set a price target for $34.00 expecting CGEM to rise to within 12 months (a possible 218.95% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cullinan Oncology (CGEM)?
The latest analyst rating for Cullinan Oncology (NASDAQ: CGEM) was provided by HC Wainwright & Co., and Cullinan Oncology reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Cullinan Oncology (CGEM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cullinan Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cullinan Oncology was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
Is the Analyst Rating Cullinan Oncology (CGEM) correct?
While ratings are subjective and will change, the latest Cullinan Oncology (CGEM) rating was a reiterated with a price target of $49.00 to $34.00. The current price Cullinan Oncology (CGEM) is trading at is $10.66, which is out of the analyst's predicted range.